Danshen Chuanxiongqin Injection is a commonly used medicine in cerebral infarction and coronary heart disease,which is recommended by many disease guidelines/consensus for cardiovascular and cerebrovascular diseases. However,there are irrational drug using in clinic,which affects the efficacy and brings safety risks. Based on clinical research evidence and expert experience,recommendations/consensus suggestion are determined through the nominal group method. The expert consensus recommends the indications,intervention time for treatment,route of drug administration,usage and dosage,course of treatment and introduces the safety in clinical application,which could provide reference for clinical use of Danshen Chuanxiongqin Injection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19540/j.cnki.cjcmm.20190509.503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Analysis of evidence map of clinical research on Chinese patent medicines in treatment of chronic pulmonary heart disease].
Zhongguo Zhong Yao Za Zhi
October 2024
Department of Cardiovascular Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
Chinese patent medicines play a crucial role in the treatment of chronic pulmonary heart disease(CPHD). Nowadays, there is still a lack of comprehensive control over clinical research evidence in this field. This study aims to summarize the clinical research on the treatment of CPHD with Chinese patent medicines using an evidence map, in order to understand the current status and deficiencies of evidence in this area.
View Article and Find Full Text PDFComparative effectiveness and safety of four traditional Chinese medicine injections with invigorating blood circulation, equivalent effect of anticoagulation or antiplatelet in acute myocardial infarction: a Bayesian network meta-analysis.
Front Pharmacol
August 2024
Department of Cardiology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China.
Traditional Chinese medicine injections with invigorating blood circulation (TCMI-IBCs), which have been used as antithrombosis therapies, are widely employed by Chinese clinicians as adjuvant therapy for acute myocardial infarction (AMI). A Bayesian network meta-analysis was conducted to contrast the effectiveness and safety of four TCMI-IBCs in AMI. Eight Databases were thoroughly searched before 31 December 2023, for randomized controlled trials (RCTs) focusing on the application of TCMI-IBCs combined with conventional treatments (CT) to treat AMI.
View Article and Find Full Text PDF[Network Meta-analysis of traditional Chinese medicine injections in treatment of chronic pulmonary heart disease].
Zhongguo Zhong Yao Za Zhi
May 2024
Heilongjiang University of Chinese Medicine Harbin 150040, China First Affiliated Hospital of Heilongjiang University of Chinese Medicine Harbin 150040, China.
Based on the network Meta-analysis, the efficacy and safety of different traditional Chinese medicine(TCM) injections in the treatment of chronic pulmonary heart disease(CPHD) were systematically evaluated. CNKI, Wanfang, VIP, SinoMed, Web of Science, PubMed, EMbase, and Cochrane Library were searched to collect randomized controlled trial(RCT) of TCM injection in the treatment of CPHD from inception to October 1, 2023. The quality of the included studies was evaluated by the bias risk assessment tool recommended by the Cochrane systematic evaluation manual version 5.
View Article and Find Full Text PDFEffectiveness and safety of Danshen injections in treatment of cardiac failure: a network meta-analysis.
Front Pharmacol
March 2024
Benxi Campus Management Committee, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.
The purpose of this network meta-analysis (NMA) was to compare the therapeutic effects of various Danshen ( Bunge [Lamiaceae; Salviae miltiorrhizae radix et rhizoma]) injections on heart failure to determine the optimal Danshen injection combined with conventional treatment. 8 databases were searched from the inception of these databases to May 2023 to collect randomized controlled trials (RCTs) on the effectiveness and safety of Danshen injections in the treatment of heart failure. This NMA was performed using Stata 16.
View Article and Find Full Text PDFNetwork pharmacology-based investigation and experimental validation of the therapeutic potential and molecular mechanism of Danshen Chuanxiongqin injection in acute pancreatitis.
Technol Health Care
July 2024
Department of Pharmacy, Zhoushan Hospital of Zhejiang Province, Zhoushan, Zhejiang, China.
Background: Danshen Chuanxiong Injection (DCI) has demonstrated significant clinical efficacy in the treatment of acute pancreatitis (AP); however, the precise molecular mechanisms underlying its therapeutic effects remain incompletely understood.
Objective: In this study, we employed network pharmacology analysis to comprehensively investigate the active components, potential targets, and signaling pathways involved in DCI-mediated treatment of AP.
Methods: We utilized the mouse pancreatic acinar cell line 266-6 to establish an cholecystokinin (CCK)-induced AP cell injury model and evaluated cell viability using the Cell counting kit-8 assay.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!